Energy is not a single study outcome
I find “cellular energy” a particularly slippery phrase in a purchase comparison. It can name a biochemical role, suggest better exercise performance or promise relief from persistent tiredness. Those meanings need different evidence. A pathway diagram can explain why researchers are interested in an ingredient without showing that a customer will feel different on Tuesday afternoon.
Before comparing providers, turn the phrase into a sentence you could evaluate. Is the offer claiming less fatigue, better concentration, improved walking or a change in a laboratory test? Name the outcome and the population. That is also why persistent symptoms deserve an appropriate clinical evaluation rather than an assumption that a NAD-related marker explains them.
A symptom trial can raise NAD without improving symptoms
In the 2025 randomized long-COVID NR trial, 58 participants completed baseline testing. NAD increased, but the controlled comparison did not show significant improvements in fatigue, cognition, sleep or mood. Exploratory before-and-after findings asked a weaker, different question and should not replace the between-group result. [1]
This is a useful reality check because the symptom outcomes were actually measured. It does not prove every future NR intervention will fail, and it does not establish a treatment conclusion for people without long COVID. It does show why an increase in NAD should not be used as shorthand for relief from fatigue.
Our close reading of the trial covers dropout and exploratory analysis in more detail. For a consumer comparison, the important point is to keep the controlled result visible. If a seller cites the study, ask whether its summary describes the randomized comparison or a change from participants’ own baseline.
Metabolic improvement is a different proposition
Dollerup’s 12-week NR study in men with obesity and insulin resistance did not find improved insulin sensitivity or whole-body glucose metabolism. Yoshino’s ten-week NMN study in selected postmenopausal women found an improvement in muscle insulin sensitivity. Different ingredients, populations and endpoints prevent either result from becoming a blanket statement about feeling more energetic. [2] [3]
I would not average these headlines into a verdict that NAD products work half the time. That would confuse separate experiments with a response rate. Instead, place the exact outcome beside each citation. A glucose-handling result can inform a metabolic question while leaving the subjective experience of fatigue unresolved.
The same problem arises when a provider uses several favorable biological terms in one sentence. Recovery, metabolism and mental clarity sound connected, but each added promise adds an evidence question. A broad sentence is not supported simply because one of its parts resembles something a trial measured.
A positive marker and a symptom answer can diverge
| Evidence | Finding | Consumer boundary |
|---|---|---|
| Long-COVID oral NR | NAD rose; randomized symptom comparisons did not show a significant advantage. [1] | A marker increase is not demonstrated fatigue relief. |
| Oral NMN, selected women | Muscle insulin sensitivity improved. [3] | This was not a general test of feeling more energetic. |
| NAD+ infusion pilot | Plasma and urine metabolites were examined over hours. [4] | No demonstrated maintenance schedule for fatigue benefit. |
Which kind of energy evidence are you reading?
- A pathwayExplains a biological role; does not measure symptom relief.
- A laboratory endpointMeasures a response in a particular sample or test.
- A functional testMeasures an activity under defined conditions.
- A symptom comparisonAsks whether people feel different from a comparison group.
Infusion evidence does not establish a recharge schedule
Grant’s small NAD+ infusion pilot investigated plasma and urine metabolites during a six-hour procedure, with sampling through eight hours. It was not a trial establishing how long a fatigue benefit lasts or how often consumers should book a clinic visit. [4]
A provider may offer a loading course followed by maintenance. That is a commercial or clinical arrangement to understand, not proof that an optimal energy schedule has been established by the pilot. Ask which human study evaluated the offered course, which symptom measure it used and what happened after the course ended.
Compare the appointment itself separately: travel, time at the location, medical evaluation, recurring obligations and the contact for concerns. Our Restore review examines recurring studio plans. A convenient location may make a service easier to use; it cannot turn a metabolite measurement into a demonstrated fatigue treatment.
Read testimonials as experience reports
A customer who describes feeling better may be reporting honestly. The limitation is in what the report can establish about cause, typical response and duration. Other changes may have occurred at the same time, and people who leave comments may differ from those who do not. A collection of positive stories is not a controlled comparison.
I would look carefully at the denominator behind any percentage. Does it refer to all customers, those who returned a questionnaire, or only people who completed several check-ins? Are the outcomes defined, and is there a comparison group? If those details are missing, keep the number out of a forecast for yourself.
The AgelessRx review explains the difference between customer check-ins and clinical evidence. The same reading rule applies to capsule brands and infusion clinics. A testimonial can help you identify a question worth asking, but it should not quietly supply the answer to a symptom claim.
Define the decision before renewal
For a conversation with your care team, describe the difficulty in concrete terms: what task is harder, when the change began and what else is relevant to your history. That makes the discussion more useful than a request to optimize a molecule. This article does not diagnose a cause or provide a regimen for ongoing symptoms.
For the purchase comparison, record what the provider promises, the evidence it supplies and the amount you would commit. Keep those three fields independent. If the only matching evidence measures a marker, say that directly. If renewal timing or fees are unclear, mark them unknown rather than completing the budget with guesses.
Use the ingredient and format explorer to avoid confusing oral NR with NAD+ injections, and the cost worksheet to compare the routine. I would judge a provider more favorably when it makes these boundaries easy to understand than when it uses an impressive energy graphic to skip them.
A useful answer can therefore be cautious and practical at the same time. Some NAD-related studies show biochemical changes; those changes do not themselves establish symptom relief. The relevant next question is which human evidence matches your actual concern and the exact offer under consideration. Until that connection is made, “energy support” remains too broad to settle the purchase.
The study claim reader lets you compare the wording of an offer with the ingredient, population and outcome in its supporting paper.
Sources
- Guzmán-Vélez et al. Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial (2025)↩ 1 ↩ 2
- Dollerup et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men (2018)↩
- Yoshino et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women (2021)↩ 1 ↩ 2
- Grant et al. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+ (2019)↩ 1 ↩ 2